SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?


To: Larry Liebman who wrote (92)11/9/1997 10:11:00 PM
From: Larry Liebman  Read Replies (1) | Respond to of 668
 
In September, the IR at CBMI reported that clinical trials were being pushed back to early '98 to expand the indications for OP-1 in kidney failure. Pre-clinical data indicated a broader utiltiy than originally anticipated. With the run of news and the stock trading <$9, it appears to be an atttractive speculation. As I understand it, both H&Q and Cowen have CBMI as a "strong buy".